Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

A Study to Evaluate a New Semi-rigid Brace, the RESILIENT Brace by Thinks Works, as a Way to Limit Curve Worsening in Kids With Idiopathic Scoliosis.

NCT07574632 · tracked via the Priya Life Science USA tracker
Sponsor
Thinks Works, PBC
Phase
Not applicable
Started
2026-05-28
Last updated
2026-06-01

Condition(s) studied

Idiopathic Scoliosis

Investigational drug(s) / intervention(s)

The RESILIENT scoliosis brace system

The RESILIENT scoliosis brace system: The RESILIENT brace is a novel semi-rigid (flexible), concealable, adjustable and modular brace with embedded sensors measuring force and wear time.

Study summary

The goal of this clinical trial is to learn if the RESILIENT Scoliosis Brace System works to treat children with idiopathic scoliosis. It will also learn about the safety, comfort, and usability of the brace. The main questions it aims to answer are:

* Can the RESILIENT brace prevent the spinal curve from progressing beyond 35 degrees during growth?
* How much does the brace correct the curve when it is first worn (in-brace correction)?
* How well do participants follow the prescribed brace wear time and force levels?
* How does wearing the brace affect quality of life and daily activities?

Researchers will study a single group of participants using the RESILIENT brace and evaluate outcomes over time using standard clinical assessments, including X-rays and patient-reported questionnaires.

Participants will:

* Be fitted with the RESILIENT brace and instructed on how to use it
* Wear the brace daily according to physician recommendations throughout their growth period
* Attend clinic visits at approximately 4-6 weeks after starting treatment and then about every 6 months for follow-up evaluations
* Undergo standard-of-care spine X-rays to monitor curve progression
* Complete questionnaires about their quality of life and experience with the brace
* Have brace wear time and applied forces monitored using sensors embedded in the device

Participants will be followed from the start of brace treatment until they are done growing and have completed treatment.

Eligibility

Sex
ALL
Min age
9 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Idiopathic Scoliosis (IS) * Age of 9 - 16 years when brace treatment is prescribed * Primary right apex main thoracic scoliosis curve with an apex of T6 or lower * Cobb angle, as measured on a standing PA spine x-ray, 20 degrees or larger and 30 degrees or less, obtained no more than 6 weeks prior to trial enrollment. * Sanders Skeletal Maturity Score of 1-5 * No prior brace treatment or surgery for scoliosis * Patient \& guardian select the RESILIENT brace for treatment * The guardian must confirm that there is cellular connectivity at the place(s) where the patient lives Exclusion Criteria: * Scoliosis other than idiopathic scoliosis: e.g. Neuromuscular, Congenital, or Syndrome Related * Age less than 9 years or older than 16 years * Sanders Skeletal Maturity Score of 6 or greater * Primary Left apex thoracic scoliosis * Primary lumbar scoliosis * Primary Right Thoracic curve with an apex above T6 * Inability to remove and apply the brace independently * Inability to respond to written and verbal questions * Patient \& Guardian select traditional TLSO for treatment * Guardian confirms there is no cellular connectivity at the place(s) where the patient lives

Primary outcome measure(s)

  • Treatment Success Based on Curve Progression at Skeletal Maturity — From baseline to skeletal maturity (approximately up to 36 months)
    Treatment success is defined as a right main thoracic Cobb angle less than or equal to 35 degrees at skeletal maturity. Treatment failure is defined as progression of the curve to greater than 35 degrees at any time during the treatment period. Cobb angle measurements are obtained from standing posteroanterior spine radiographs and assessed by independent reviewers blinded to patient information. Skeletal maturity is defined as a Sanders Skeletal Maturity Score of ≥7B, absence of longitudinal height increase over the preceding 6 months, and, for female participants, at least 18 months post-menarche.

Trial sites (1)

FacilityCityRegionStatus
Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07574632 on ClinicalTrials.gov ↗ ← All trials in the USA